logo
#

Latest news with #JeffCole

Two City Council candidate primary forums set for this week
Two City Council candidate primary forums set for this week

Yahoo

time12 hours ago

  • Politics
  • Yahoo

Two City Council candidate primary forums set for this week

Jun. 8—WATERTOWN — Voters will have to chances to hear what City Council primary candidates to say about city issues during two candidate forums this week. On Tuesday, a candidate forum will be held from 6 p.m. to 8 p.m. Tuesday at the Italian American Civic Association, 192 Bellew Ave. Live @ Five radio host Glen Curry will moderate the forum. It will broadcast live on WATN AM, 1240. The second forum will be from 7 p.m. to 9 p.m.. on Thursday at Jefferson Community College. Channel 7 news anchor Jeff Cole will be the moderator. The forum will be broadcast on WWNY-TV. Seven candidates will participate in both forums. City Councilman Cliff G. Olney III is being excluded from the forums because he's not on the ballot for the June 24 primary. The public is invited to attend both forums.

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Yahoo

time03-04-2025

  • Business
  • Yahoo

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Management Available for One-to-One Meetings PONTE VEDRA, Fla., April 03, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy. Additionally, Dr. Ferguson will attend the 13th annual CMO Summit 360° ® taking place on April 7-8, the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels, and geographic locations. Expanding its industry and business development engagement, the Company will be at the BIO International Convention, the world's largest biotechnology conference, from June 16-19, 2025 in Boston, MA, to meet with potential partners and collaborators to advance and enhance our lead program, tecarfarin and to build our pipeline in specialized cardiovascular therapeutics. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel, and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With tecarfarin, Cadrenal aims to meet the unmet needs of these patient populations by relieving them and their healthcare providers of some of warfarin's greatest clinical challenges. Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. View source version on Contacts Corporate and Investor Relations Lisa DeScenzaLaVoieHealthScience(978) 395-5970ldescenza@ Media Andrew KordaLaVoieHealthScience(617) 865-0043akorda@ Sign in to access your portfolio

Atlas Tube Unveils the HSS Connections Hub(TM): Complimentary Tools and Expert Support to Help Structural Engineers Streamline HSS Connection Design
Atlas Tube Unveils the HSS Connections Hub(TM): Complimentary Tools and Expert Support to Help Structural Engineers Streamline HSS Connection Design

Yahoo

time01-04-2025

  • Business
  • Yahoo

Atlas Tube Unveils the HSS Connections Hub(TM): Complimentary Tools and Expert Support to Help Structural Engineers Streamline HSS Connection Design

CHICAGO, IL / / April 1, 2025 / Atlas Tube, a division of Zekelman Industries, today introduces its HSS Connections Hub™ featuring an innovative suite of engineering resources designed to simplify Hollow Structural Sections (HSS) connection design for structural engineers and fabricators. The Connections Hub is built to: Save time designing HSS connections. Optimize HSS connection designs for fabrication. Improve team collaboration and project sharing. Eliminate outdated and highly customized spreadsheets. The Connections Hub includes a variety of downloadable typical connection details and advanced HSS design calculators, allowing engineers to accurately design a variety of connections while reducing costs and complexity. The initial rollout includes the most common detail sheets, with many more to be added in the weeks and months to come. "By providing fabrication-friendly HSS connection designs and calculations, the Connections Hub fills a void for engineers looking to realize the benefits of HSS in their designs," said Jeff Cole, President, Atlas Tube. "We will continue growing resources in the Connections Hub, so that engineers and steel detailers have one trusted source for HSS connection designs that are easier to fabricate and reduce costs throughout the construction process." The Connections Hub calculators will be used to generate optimized designs for specific loads, minimizing inefficiencies that can create late changes on a project. Additionally, the platform provides professional-grade reports that can be submitted for project stakeholder approvals, streamlining communication between engineers, fabricators, and connection detailers. Learn more about the Connections Hub at Additionally, visitors to Atlas Tube booth 225 at the 2025 North American Steel Construction Conference (NASCC) held in Louisville, Ky., April 2-4, will have the opportunity to see live demonstrations and learn how these tools can immediately benefit their current HSS connection designs. About Zekelman Zekelman is a family of operating companies which include Atlas Tube, Picoma, Sharon Tube, Wheatland Tube, Western Tube, and Z Modular. With 23 manufacturing locations and 3,200+ teammates across North America, the company is the leading independent manufacturer of hollow structural sections (HSS) and steel pipe, and the top producer of electrical conduit and elbows, couplings, and nipples in North America. Zekelman - Believe in What You Build™. For more information, visit Media Contacts: Amanda DonovanDirector of Marketing Communications, Owen SereyManagement Supervisor - Public Relations, Mower513.639.7455oserey@ SOURCE: Zekelman Industries View the original press release on ACCESS Newswire Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store